Comparative Pharmacology
Head-to-head clinical analysis: MARCAINE HYDROCHLORIDE PRESERVATIVE FREE versus POLOCAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARCAINE HYDROCHLORIDE PRESERVATIVE FREE versus POLOCAINE.
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE vs POLOCAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine blocks sodium ion channels in nerve cell membranes, preventing the generation and conduction of nerve impulses, resulting in local anesthesia.
Local anesthetic that stabilizes the neuronal membrane by inhibiting the influx of sodium ions, thereby blocking nerve impulse propagation.
Local infiltration: up to 30 mL of 0.5% (150 mg) per dose. Peripheral nerve block: 30-40 mL of 0.5% (150-200 mg). Epidural: 15-20 mL of 0.5% (75-100 mg). Maximum single dose: 2.5 mg/kg (225 mg for 90 kg). Repeat doses after 3 hours, max 400 mg/24h.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life in adults: 2.7 ± 1.2 hours (range 1.5-5.5 hours). In neonates, half-life is prolonged to approximately 8.1 ± 8.2 hours due to immature hepatic and renal function.
Terminal elimination half-life approximately 1.5-2.0 hours in adults; prolonged to 3-5 hours in hepatic impairment and neonates.
Primarily hepatic metabolism to 2,6-pipecoloxylidide (PPX) and subsequent renal excretion. Renal excretion of unchanged bupivacaine accounts for approximately 5-10% of the dose. The remainder is eliminated as metabolites (PPX and others) in urine. Fecal excretion is negligible.
Hepatic metabolism to 2,6-xylidine and 4-hydroxy-2,6-xylidine; <10% excreted unchanged in urine; approximately 70-80% of metabolites excreted renally, with <5% in feces.
Category C
Category C
Local Anesthetic
Local Anesthetic